Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial [Hematologic Malignancy]
Conclusion
These final results from the DASISION trial continue to support dasatinib 100 mg once daily as a safe and effective first-line therapy for the long-term treatment of CML-CP.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Cortes, Saglio, Kantarjian, Baccarani, Mayer, Boque, Shah, Chuah, Casanova, Bradley-Garelik, Manos, Hochhaus Tags: Clinical Trials, Biological Therapy, Hematologic Hematologic Malignancy Source Type: research
More News: Cancer & Oncology | Chronic Leukemia | Chronic Myeloid Leukaemia | Clinical Trials | Gleevec | Hematology | Leukemia | Molecular Biology | Statistics | Study